Roche Looks Ahead To 2011, But Avastin Woes And Other Concerns Could Pose Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
After several setbacks in 2010, the Swiss Pharma lowers its guidance on its best-selling drug and braces for the results from a key study.